stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) Gross margin
Arcutis Biotherapeutics, Inc.'s gross margin over the twelve months to 30 September 2026 was 91.2%, up 0.9 percentage points from fiscal 2025 (90.2%). Over the past ten years it has ranged from 0.00% (fiscal 2021) to 91.6% (fiscal 2023); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 90.2% | (0.03) |
| FY2024 | 90.3% | (1.36) |
| FY2023 | 91.6% | 12.09 |
| FY2022 | 79.5% | 79.54 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 91.3% | (0.24) |
| Jun 2026 | 91.6% | 0.86 |
| Mar 2026 | 90.7% | (0.25) |
| Dec 2025 | 91.0% | (0.28) |
| 24 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RLAY Relay Therapeutics, Inc. compare | 100.0% |
| ABCL AbCellera Biologics Inc. compare | 100.0% |
| DNTH Dianthus Therapeutics, Inc. compare | 100.0% |
| TNGX Tango Therapeutics, Inc. compare | 100.0% |
| ARQT Arcutis Biotherapeutics, Inc. | 91.2% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 56.6% |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| DFTX Definium Therapeutics, Inc. compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement